

Wolfgang Brück

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5689075/publications.pdf>

Version: 2024-02-01

34
papers

6,866
citations

361045

20
h-index

377514

34
g-index

34
all docs

34
docs citations

34
times ranked

6620
citing authors

#	ARTICLE	IF	CITATIONS
1	Iron Heterogeneity in Early Active Multiple Sclerosis Lesions. <i>Annals of Neurology</i> , 2021, 89, 498-510.	2.8	22
2	Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes. <i>Neurology</i> , 2021, 97, e1906-e1913.	1.5	18
3	B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 25690-25699.	3.3	44
4	Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	13
5	B cell depletion can be effective in multiple sclerosis but failed in a patient with advanced childhood cerebral X-linked adrenoleukodystrophy. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641986813.	1.5	1
6	A case of CLIPPERS syndrome responsive to tocilizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e545.	3.1	9
7	CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. <i>Nature Communications</i> , 2019, 10, 5779.	5.8	87
8	Therapy of highly active pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 72-80.	1.4	60
9	Differences in the Responses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 428.	4.5	54
10	CLIPPERS with longitudinally extensive transverse myelitis: Role of T versus B cells. <i>Journal of the Neurological Sciences</i> , 2018, 385, 96-98.	0.3	7
11	Differential somatostatin, CXCR4 chemokine and endothelin A receptor expression in WHO grade IV astrocytic brain tumors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1227-1237.	1.2	15
12	Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 9773-9778.	3.3	82
13	Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy. <i>Neurology</i> , 2018, 91, e359-e363.	1.5	20
14	An updated histological classification system for multiple sclerosis lesions. <i>Acta Neuropathologica</i> , 2017, 133, 13-24.	3.9	436
15	Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. <i>Molecular Therapy</i> , 2017, 25, 2620-2634.	3.7	199
16	The Early Adaptive Immune Response in the Pathophysiological Process of Pneumococcal Meningitis. <i>Journal of Infectious Diseases</i> , 2017, 215, 150-158.	1.9	9
17	Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. <i>Acta Neuropathologica</i> , 2016, 132, 43-58.	3.9	75
18	Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e257.	3.1	178

#	ARTICLE	IF	CITATIONS
19	Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e233.	3.1	15
20	Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e204.	3.1	53
21	Glial Cells Express Nuclear Nrf2 After Fumarate Treatment for Multiple Sclerosis and Psoriasis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e99.	3.1	17
22	Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. <i>Annals of Neurology</i> , 2015, 78, 710-721.	2.8	485
23	Murine K2P5.1 Deficiency Has No Impact on Autoimmune Neuroinflammation due to Compensatory K2P3.1- and KV1.3-Dependent Mechanisms. <i>International Journal of Molecular Sciences</i> , 2015, 16, 16880-16896.	1.8	4
24	Complement-associated neuronal loss in a patient with CASPR2 antibody-associated encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e75.	3.1	50
25	Natalizumab analogon therapy is effective in a <sc>B</sc> cell-dependent multiple sclerosis model. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 814-831.	1.8	6
26	Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. <i>Neurology</i> , 2015, 84, 148-158.	1.5	49
27	Pathologic heterogeneity persists in early active multiple sclerosis lesions. <i>Annals of Neurology</i> , 2014, 75, 728-738.	2.8	110
28	Accumulation and therapeutic modulation of 6-sulfo LacNAc ⁺ dendritic cells in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e33.	3.1	28
29	Anti-inflammatory Disease Therapies. <i>Toxicologic Pathology</i> , 2012, 40, 122-125.	0.9	1
30	Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. <i>Annals of Neurology</i> , 2012, 72, 385-394.	2.8	67
31	Inflammatory Cortical Demyelination in Early Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2011, 365, 2188-2197.	13.9	922
32	Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. <i>Lancet, The</i> , 2005, 366, 579-582.	6.3	411
33	Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. <i>Annals of Neurology</i> , 2000, 47, 707-717.	2.8	2,892
34	Monocyte/macrophage differentiation in early multiple sclerosis lesions. <i>Annals of Neurology</i> , 1995, 38, 788-796.	2.8	427